Lilly licenses Amylin's diabetes drug; deal ends with rights returned to Amylin
- Large Molecule
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Includes Contract
- Product or Technology Swap
- R+D and Marketing-Licensing
- Includes Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.